Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR2 fusion Derazantinib intrahepatic cholangiocarcinoma sensitive detail...
IDH1 R132S Dasatinib intrahepatic cholangiocarcinoma sensitive detail...
IDH1 R132S Saracatinib intrahepatic cholangiocarcinoma sensitive detail...
IDH1 R132C Saracatinib intrahepatic cholangiocarcinoma sensitive detail...
IDH1 R132C Dasatinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 F276C Infigratinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 fusion FGFR2 M538I Infigratinib intrahepatic cholangiocarcinoma decreased response detail...
FGFR2 fusion FGFR2 N550H Infigratinib intrahepatic cholangiocarcinoma decreased response detail...
FGFR2 fusion FGFR2 E566A Infigratinib intrahepatic cholangiocarcinoma decreased response detail...
FGFR2 fusion FGFR2 H683L Infigratinib intrahepatic cholangiocarcinoma decreased response detail...
FGFR2 fusion FGFR2 N550K Infigratinib intrahepatic cholangiocarcinoma resistant detail...
FGFR2 fusion FGFR2 V565F Infigratinib intrahepatic cholangiocarcinoma resistant detail...
FGFR2 fusion FGFR2 L618V Infigratinib intrahepatic cholangiocarcinoma resistant detail...
FGFR2 fusion FGFR2 K660M Infigratinib intrahepatic cholangiocarcinoma resistant detail...
FGFR2 fusion FGFR2 K715R Infigratinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 fusion FGFR2 K715R Zoligratinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 fusion FGFR2 M538I Zoligratinib intrahepatic cholangiocarcinoma decreased response detail...
FGFR2 fusion FGFR2 N550H Zoligratinib intrahepatic cholangiocarcinoma decreased response detail...
FGFR2 fusion FGFR2 V565F Zoligratinib intrahepatic cholangiocarcinoma decreased response detail...
FGFR2 fusion FGFR2 E566A Zoligratinib intrahepatic cholangiocarcinoma decreased response detail...
FGFR2 fusion FGFR2 H683L Zoligratinib intrahepatic cholangiocarcinoma decreased response detail...
FGFR2 fusion FGFR2 N550K Zoligratinib intrahepatic cholangiocarcinoma resistant detail...
FGFR2 fusion FGFR2 L618V Zoligratinib intrahepatic cholangiocarcinoma resistant detail...
FGFR2 fusion FGFR2 K660M Zoligratinib intrahepatic cholangiocarcinoma resistant detail...
FGFR2 fusion FGFR2 V565F Futibatinib intrahepatic cholangiocarcinoma resistant detail...
FGFR2 fusion FGFR2 K715R Futibatinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 fusion FGFR2 M538I Futibatinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 fusion FGFR2 N550H Futibatinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 fusion FGFR2 N550K Futibatinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 fusion FGFR2 E566A Futibatinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 fusion FGFR2 L618V Futibatinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 fusion FGFR2 K660M Futibatinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 fusion FGFR2 H683L Futibatinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 H167_N173del Zoligratinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 H167_N173del FGFR2 L617F Zoligratinib intrahepatic cholangiocarcinoma predicted - resistant detail...
RET fusion Pralsetinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 Y376C Fexagratinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 fusion Futibatinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 rearrange Futibatinib intrahepatic cholangiocarcinoma sensitive detail...
BRAF V600E Trametinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR1 N546D Futibatinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 H167_N173del Futibatinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 I288_E295delinsT Zoligratinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 H167_N173del FGFR2 L618F Zoligratinib intrahepatic cholangiocarcinoma predicted - resistant detail...
FGFR2 H167_N173del FGFR2 L618F Futibatinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
BRAF V600E Dabrafenib + Trametinib intrahepatic cholangiocarcinoma sensitive detail...
BRAF L597Q FGFR2 H167_N173del FGFR2 L618F Futibatinib intrahepatic cholangiocarcinoma predicted - resistant detail...
BRAF L597Q FGFR2 H167_N173del FGFR2 L618F LY3214996 intrahepatic cholangiocarcinoma no benefit detail...
BRAF L597Q FGFR2 H167_N173del FGFR2 N550K FGFR2 L618F NRAS Q61K LY3214996 intrahepatic cholangiocarcinoma predicted - resistant detail...
MLH1 negative Dostarlimab-gxly intrahepatic cholangiocarcinoma sensitive detail...
MSH6 negative Dostarlimab-gxly intrahepatic cholangiocarcinoma sensitive detail...
MLH1 negative Pembrolizumab intrahepatic cholangiocarcinoma sensitive detail...
MSH6 negative Pembrolizumab intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 F276C Pazopanib intrahepatic cholangiocarcinoma predicted - sensitive detail...
IDH1 act mut Olutasidenib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 W290C Futibatinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 C383R Futibatinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR1 M563T Futibatinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 mutant Derazantinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 amp Derazantinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 C382R Pemigatinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
IDH1 R132C IDH2 R172K Ivosidenib intrahepatic cholangiocarcinoma predicted - resistant detail...
IDH1 R132C IDH1 D279N Ivosidenib intrahepatic cholangiocarcinoma predicted - resistant detail...
IDH1 R132C Olaparib + Radiotherapy intrahepatic cholangiocarcinoma sensitive detail...
IDH1 R132H Olaparib + Radiotherapy intrahepatic cholangiocarcinoma sensitive detail...
EML4 - ALK Ensartinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 fusion HMPL-453 intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR1 over exp Infigratinib intrahepatic cholangiocarcinoma no benefit detail...
FGFR1 over exp Futibatinib intrahepatic cholangiocarcinoma no benefit detail...
FGFR1 over exp Pemigatinib intrahepatic cholangiocarcinoma no benefit detail...
FGFR2 T370_A371delinsC Lenvatinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 fusion 3HP-2827 intrahepatic cholangiocarcinoma predicted - sensitive detail...
RET fusion Selpercatinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR3 S249C FGFR3 N540K Futibatinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 C382R Erdafitinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 C382R FGFR2 N550D Erdafitinib intrahepatic cholangiocarcinoma predicted - resistant detail...
FGFR2 C382R FGFR2 N549D Erdafitinib intrahepatic cholangiocarcinoma predicted - resistant detail...
FGFR2 C382R FGFR2 N549D Futibatinib intrahepatic cholangiocarcinoma conflicting detail...
FGFR2 C383R FGFR2 N550D Lirafugratinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 Y375C Futibatinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 C382R Futibatinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
BRAF F595L Cetuximab + Trametinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02428855 Phase II Dasatinib Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma Completed USA 0
NCT02632305 Phase II Cisplatin + Gemcitabine + Nab-paclitaxel A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer (AX-CSARC) Active, not recruiting CAN 0
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Active, not recruiting USA 1
NCT02834780 Phase I H3B-6527 Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma Completed USA | ITA | GBR | FRA | ESP | CAN | BEL 4
NCT03230318 Phase II Derazantinib Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (FIDES-01) Completed USA | ITA | IRL | GBR | FRA | ESP | DEU | CHE | CAN | BEL 1
NCT03684811 Phase Ib/II Cisplatin + Gemcitabine + Olutasidenib Azacitidine + Olutasidenib Olutasidenib Nivolumab + Olutasidenib A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation Completed USA | GBR | FRA | ESP | AUS 1
NCT03781934 Phase Ib/II MIV-818 A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Active, not recruiting GBR | ESP | BEL 1
NCT03942328 Phase II Atezolizumab + Bevacizumab + PCV13 vaccine PCV13 vaccine Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer Recruiting USA 0
NCT04003636 Phase III Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) (KEYNOTE-966) Active, not recruiting USA | TUR | NZL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG 8
NCT04057365 Phase II DKN-01 + Nivolumab A Single Arm Phase II Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) Terminated USA 0
NCT04093362 Phase III Futibatinib Cisplatin + Gemcitabine Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements (FOENIX-CCA3) Terminated USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | BRA | BEL | AUS | ARG 8
NCT04175912 Phase II Carboplatin + MLN4924 + Paclitaxel MLN4924 Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver Active, not recruiting USA 0
NCT04203160 Phase Ib/II Cisplatin + Gemcitabine Cisplatin + CPI-613 + Gemcitabine Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) Completed USA 0
NCT04301011 Phase Ib/II TBio-6517 Pembrolizumab + TBio-6517 Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (RAPTOR) Terminated USA | CAN 1
NCT04301778 Phase II Axatilimab + Durvalumab Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma Completed USA 0
NCT04306367 Phase II Olaparib + Pembrolizumab Study of Pembrolizumab and Olaparib in Bile Duct Cancer Active, not recruiting USA 0
NCT04466891 Phase II ZW25 A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers (HERIZON-BTC-01) Completed USA | ITA | GBR | FRA | ESP | CAN 3
NCT04704154 Phase II Nivolumab + Regorafenib A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors Completed USA | ITA | GBR | FRA | BEL 3
NCT04708067 Phase I Bintrafusp alfa Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma Active, not recruiting USA 0
NCT04907851 Phase II Denosumab + RXC004 Denosumab + Pembrolizumab + RXC004 A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) (KEYNOTE-E86) Completed GBR | AUS 0
NCT04941287 Phase II Atezolizumab + Varlilumab Atezolizumab + Cobimetinib + Varlilumab Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of A Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer Active, not recruiting USA 0
NCT04969887 Phase II Ipilimumab + Nivolumab Combination Immunotherapy in Rare Cancers Under InvesTigation (MOST-CIRCUIT) Active, not recruiting NZL | AUS 0
NCT04976634 Phase II Belzutifan + Lenvatinib + Pembrolizumab Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) Recruiting USA | NZL | NLD | ISR | FRA | ESP | BEL | AUS 2
NCT04989218 Phase Ib/II Cisplatin + Durvalumab + Gemcitabine + Tremelimumab Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC) (ICC) Terminated USA 0
NCT05007106 Phase II MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Active, not recruiting USA | TUR | POL | NLD | ITA | ISR | FRA | ESP | DEU | CAN 5
NCT05174650 Phase II Atezolizumab + Derazantinib Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements Active, not recruiting DEU 0
NCT05220722 Phase Ib/II Pembrolizumab + SD-101 Ipilimumab + Nivolumab + SD-101 Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors Active, not recruiting USA 0
NCT05221320 Phase II Hydroxychloroquine + Ulixertinib Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies Terminated USA 0
NCT05223816 Phase II Nivolumab + VG161 VG161 An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma Recruiting USA 0
NCT05239169 Phase II Capecitabine + Durvalumab + Tremelimumab Durvalumab + Tremelimumab Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer Active, not recruiting DEU 0
NCT05286814 Phase II Fluorouracil + Leucovorin + NHS-IL12 + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + NHS-IL12 M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma Recruiting USA 0
NCT05325866 Phase I Bemarituzumab A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301) Recruiting USA | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DNK | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG 4
NCT05506943 Phase II Paclitaxel CTX-009 + Paclitaxel A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Active, not recruiting USA 0
NCT05512377 Phase II BI 907828 Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder Active, not recruiting USA | GBR | FRA | ESP | DEU | CHE | BEL | AUS 5
NCT05514912 Phase II Cisplatin + Gemcitabine + Nab-paclitaxel Cisplatin + Gemcitabine + Infigratinib + Nab-paclitaxel Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial Withdrawn 0
NCT05564403 Phase II Fluorouracil + Leucovorin + Oxaliplatin Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) Recruiting USA 0
NCT05565794 Phase II Pemigatinib Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements Recruiting DEU 0
NCT05627063 Phase I ABSK121 A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors Recruiting USA 1
NCT05655949 Phase II Cisplatin + Durvalumab + Gemcitabine + Yttrium-90 microsphere therapy Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio Recruiting USA 0
NCT05967182 Phase II Cisplatin + Gemcitabine + Pembrolizumab A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma Recruiting USA 0
NCT06017297 Phase II Cisplatin + Durvalumab + Gemcitabine + Tremelimumab Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma (ESR-22-21719) Withdrawn 0
NCT06050252 Phase II Cisplatin + Durvalumab + Gemcitabine Durvalumab With Gemcitabine and Cisplatin for the Treatment of High Risk Resectable Liver Cancer Before Surgery Recruiting USA 0
NCT06058663 Phase I Durvalumab + Tremelimumab Radioembolization With Tremelimumab and Durvalumab for Locally Advanced, Unresectable Intrahepatic Cholangiocarcinoma Recruiting USA 0
NCT06160752 Phase I TYRA-200 Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations (SURF201) Recruiting USA 0
NCT06282575 Phase III Cisplatin + Durvalumab + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab Cisplatin + Durvalumab + Gemcitabine + ZW25 Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab + ZW25 Cisplatin + Gemcitabine + ZW25 Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer Recruiting USA | SWE | ROU | ITA | ISR | FRA | FIN | ESP | CAN | ARG 8
NCT06360354 Phase I AMG193 + Cisplatin + Gemcitabine + Pembrolizumab AMG193 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin AMG193 + Gemcitabine + Nab-paclitaxel A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion Recruiting USA | NLD | ITA | GRC | FRA | ESP | DNK | DEU | CAN | BEL | AUS 2
NCT06375915 Phase II Cisplatin + Durvalumab + Gemcitabine Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy (PM-CARE) Recruiting ITA 0
NCT06529718 Phase II Fluorouracil + Leucovorin + Oxaliplatin Ivonescimab Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients (SEVILLA) Not yet recruiting GBR | FRA | BEL 0
NCT06546969 Phase I Cisplatin + Durvalumab + Gemcitabine Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer Recruiting USA 0
NCT06569225 Phase II AZD2936 + Cisplatin + Gemcitabine + Nab-paclitaxel Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCA (NEOLANGIO) Not yet recruiting CAN 0